Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Rhea-AI Summary

VolitionRx (NYSE AMERICAN: VNRX) reported significant progress in its Nu.Q® Discover program, which has an estimated $200 million annual addressable market. The program now serves over 20 global clients with 14 state-of-the-art immunoassays for epigenetic profiling.

The company's technology was validated in a peer-reviewed publication in the Journal of Biological Chemistry. The largest ongoing project involves a longitudinal Phase 1/2b study expected to complete in 2026, with projected revenue in the hundreds of thousands of dollars.

Volition is exploring co-marketing partnerships and anticipates signing new deals in the coming months, with potential for multi-million dollar partnerships if Nu.Q® assays advance to companion diagnostic use.

Positive

• Growing client base with over 20 global customers
• Scientific validation through peer-reviewed publication
• Secured contracts with projected revenue in hundreds of thousands of dollars
• Potential for multi-million dollar partnerships through companion diagnostic development
• Strong repeat orders from existing clients

Negative

• Relatively small total addressable market of $200M compared to other company segments

Insights

Biotech Investment Analyst

VolitionRx's Nu.Q® Discover platform shows promising commercial traction with revenue potential despite modest $200M market size.

VolitionRx's update on their Nu.Q® Discover program reveals meaningful commercial progress for their epigenetic platform technology. The company has disclosed that the program now serves over 20 clients worldwide, indicating significant market adoption of their nucleosome quantification technology. Despite targeting a relatively modest total addressable market of $200 million annually compared to their other business segments, this platform is generating early revenue and validation.

The core value proposition lies in Nu.Q® Discover's portfolio of 14 immunoassays that enable high-throughput epigenetic profiling—an increasingly valuable capability in pharmaceutical R&D and precision medicine development. Their largest ongoing project, a longitudinal Phase 1/2b study extending to 2026, is projected to generate hundreds of thousands in revenue, demonstrating the substantial per-client value potential.

What's particularly notable is the strategic positioning of this service. By embedding their technology into pharma companies' clinical trials as exploratory biomarkers now, VolitionRx is creating a pathway to potentially more valuable companion diagnostic partnerships later—deals that could be worth millions in recurring revenue if clinical trials advance successfully. This represents a classic "foot-in-the-door" approach that could yield significant long-term value.

The scientific validation through peer-reviewed publication adds credibility to their platform, while their pursuit of co-marketing partnerships suggests a capital-efficient approach to scaling. While modest compared to other potential revenue streams, the Nu.Q® Discover program appears to be successfully transitioning from pure R&D to commercial reality, providing investors tangible evidence of the platform's market viability.

 HENDERSON, Nev., July 16, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides an update on the significant commercial and scientific progress of its Nu.Q^® Discover program.

With an estimated total addressable market of $200 million annually ^[1], Nu.Q^® Discover targets a smaller market than our other larger pillars, but it is proving to be a strong source of early revenue and is validating the wide applicability and utility of our Nu.Q^® platform with some of the world's biggest healthcare companies. With a powerful portfolio of 14 state-of-the-art immunoassays, Nu.Q^® Discover is now serving over 20 clients worldwide, accelerating disease research and drug development across multiple therapeutic areas. Built on Volition's proprietary nucleosome quantification technology, Nu.Q^® Discover offers unparalleled insight through high-throughput epigenetic profiling as a service to large Pharma and diagnostic companies for their own development programs. The Nu.Q^® platform's versatility across biological samples and disease models was recently validated in a peer-reviewed publication in the Journal of Biological Chemistry titled: "High-throughput epigenetic profiling immunoassays for accelerated disease research and clinical development."

Volition is committed to expanding the Nu.Q^® Discover offering and delivering significant value to the life sciences community. The company anticipates continued growth in 2025, including multiple new contracts, building on the strong foundation of scientific excellence and global commercial traction established to date.

Dr. Jasmine Kway, Chief Executive Officer, Singapore Volition said:

"We've seen strong and growing demand for Nu.Q^® assays as exploratory biomarkers in 3^rd parties' multi-national clinical trials, with multiple global clients placing repeat orders. The largest of these projects has projected revenue in the hundreds of thousands of dollars, for an ongoing longitudinal Phase 1/2b study targeting completion in 2026.

"Our robust pipeline and ongoing service expansion suggests continued strong Nu.Q^® Discover revenue growth this year.

"Pharma companies are using Nu.Q^® assays as exploratory biomarkers today — and if/when they advance to companion diagnostic use, this could translate into high-value, multi-million dollar, long-term partnerships.

"We're also actively exploring co-marketing partnerships to meet the demand for Nu.Q^® Discover we are seeing worldwide and hope to be able to sign such a deal in the coming months."

About Nu.Q^® Discover

Nu.Q^® Discover empowers pharmaceutical and biotech developers with rapid high-throughput epigenetic profiling across key biological processes. The platform supports the entire drug development continuum—from preclinical studies to clinical validation—with biomarkers designed to:

• Assess disease severity
• Monitor treatment response
• Deepen understanding of disease mechanisms

Its applications span oncology, neurodegenerative and autoimmune diseases and NETosis—making it one of the most versatile epigenetic solutions on the market today.
To learn more about Nu.Q^® Discover or to request a collaboration, visit https://volition.com/nu-q-discover-work-with-us/#working-with-us.

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.  

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries:

Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620

Investor Relations:
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the total addressable market for Nu.Q® Discover, , Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing, distribution and/or other agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q^® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.  Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

^[1] Data on file, Volition Total Addressable Market Model

Photo: https://mma.prnewswire.com/media/2732448/VolitionRxLimited_Assays.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuq-discover-expands-global-adoption-and-epigenetic-innovation-302506707.html

SOURCE VolitionRx Limited

FAQ

What is the market size for VolitionRx's Nu.Q® Discover program?

The Nu.Q® Discover program has an estimated total addressable market of $200 million annually, though it represents a smaller market compared to the company's other pillars.

How many clients does VNRX's Nu.Q® Discover program currently serve?

Nu.Q® Discover currently serves over 20 clients worldwide, including large pharmaceutical and diagnostic companies.

What is the timeline for VolitionRx's largest ongoing clinical study?

The largest ongoing project is a longitudinal Phase 1/2b study targeting completion in 2026, with projected revenue in the hundreds of thousands of dollars.

How many immunoassays are included in VNRX's Nu.Q® Discover portfolio?

The Nu.Q® Discover program includes a portfolio of 14 state-of-the-art immunoassays for high-throughput epigenetic profiling.

What are the potential partnership opportunities for VolitionRx's Nu.Q® program?

VolitionRx is exploring co-marketing partnerships and has potential for multi-million dollar, long-term partnerships if Nu.Q® assays advance to companion diagnostic use.